GE Healthcare is selling its BioPharma business to Danaher Corp. for $21.4bn, including $21bn cash as well as certain pension liabilities in a major deal set to provide GE with a much-needed cash injection.
The biopharma business, which sells chromatography hardware and consumables, cell culture media, single-use technologies, and development instrumentation accounted for 15% of GE Healthcare business revenue in 2018. According to GE,...